Transasia Bio-Medicals Ltd., India’s No. 1 In-vitro Diagnostic (IVD) Company and among the leading global players globally focused on emerging markets, today announced that it is bringing its international hematology range for the first time to Indian market. Backed by European R&D, the 3-Part Differential (3PD) to 5-Part Differential (5PD) fully automated hematology analyzers, reagents and controls will be commercially launched from April 1, 2019 across India. These next-generation instruments include a number of features to help institutions, clinicians and laboratory technologists offer accurate diagnosis. Manufactured by Erba Lachema (100% owned subsidiary of Transasia) in Europe, the H 360, H 560 and ELite 580 hematology analyzers are widely used in the European market. Hematology analyzers are extensively used in patient and research settings to count and characterize blood cells for disease detection and monitoring. Basic analyzers return a complete blood count (CBC) with a three-part differential white blood cell (WBC) count. Sophisticated analyzers measure cell morphology and can detect small cell populations to diagnose rare blood conditions.
Formally introducing the range, Suresh Vazirani, Chairman & Managing Director, Transasia Bio-Medicals Ltd., said, “Today marks a major milestone in our quest to make high quality diagnostics affordable for the masses in India. The international hematology range that we are introducing in India is comparable to the best in the world. Which means that the more these equipment penetrate the Indian market, the more affordable and accessible will be such basic tests for the larger population. This really moves the needle on better preventive healthcare in India, over the long-term. It is a proud moment for all of us at Transasia and it is apt that this coincides with the completion of Transasia’s 40th anniversary celebration.”
Added Mala Vazirani, Executive Director, Transasia Bio-Medicals Ltd., “Eastern region is the most loyal market and among the fastest growing markets for Transasia in India. West Bengal is the largest market for us in this region constituting 8% of our national revenues. The new hematology range will be of relevance to West Bengal and eastern region which has unique and high incidence of hemoglobinopathies like Thalassemia, sickle cell anemia besides others. It always gives us immense satisfaction to be able to make a difference to the masses through accurate diagnostics which is affordable.”
As per a 2018 Union Ministry of Health and Family Welfare study, India has the largest number of children with Thalassemia major in the world (150,000). There are almost 42 million carriers of β- thalassemia trait. While the prevalence averages 3-4% across India, a higher frequency has been observed in certain communities, such as Sindhis, Punjabis, Gujaratis, Bengalis, Mahars, Kolis, Saraswats, Lohanas and Gaurs. An estimated 10,000-15,000 babies with thalassemia major are born annually. HbE, is the variant hemoglobin that significantly contributes to hemoglobinopathies, especially in West Bengal and North East where the carrier frequency can be as high as 50%. Sickle cell disease prevalence is variable, with very high frequency in many tribal communities.
In his comments, Adam Mellick, Global Product Manager – Hematology, Erba Group, UK, said, “Accepted world-over for their quality, precision and ease-of-operation, the Erba range of hematology products will bring about an increase in adoption of automated hematology testing among Indian diagnostic labs. The range offers a new wave of high performance and convenience, making it an ideal choice for every lab. It also provides holistic solutions for clinical testing for general and targeted diagnostics which is an added advantage for pediatric and geriatric population. Other unique features include flagging of abnormal samples, RFID, large colored LCD touch screen, customizable reporting formats, ability to connect to a Laboratory Information System (LIS) for result output and the ready-to-use reagents being cyanide free and environment-friendly. By addressing many challenges that labs and pathologists face, Transasia is helping healthcare professionals (HCPs) focus on giving patients the best possible care.”
Added Suresh Vazirani, “As per industry reports in 2018, India’s medical devices industry is pegged at a $5.2 billion (Rs. 35,097.40 crore), most of which is imported. It is players like Transasia who are at the forefront of changing it and driving Make in India.”